<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ragkousis,A.</style></author><author><style face="normal" font="default" size="100%">Kazantzis,D.</style></author><author><style face="normal" font="default" size="100%">Georgalas,I.</style></author><author><style face="normal" font="default" size="100%">Theodossiadis, P</style></author><author><style face="normal" font="default" size="100%">Kroupis, C.</style></author><author><style face="normal" font="default" size="100%">Chatziralli, I</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Association of PON1, APOE and SDF-1 Gene Polymorphisms with Treatment Response to Intravitreal Anti-VEGF Treatment in Patients with Retinal Vein Occlusion</style></title><secondary-title><style face="normal" font="default" size="100%">Semin.Ophthalmol.</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2023/11/24/</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">PM:37997789</style></url></web-urls></urls><pages><style face="normal" font="default" size="100%">1 - 8</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">PURPOSE: The purpose of this study was to determine whether specific genetic polymorphisms affect the response to intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment in patients with macular oedema secondary to retinal vein occlusion (RVO). METHODS: Participants in this prospective study were 50 patients with macular oedema secondary to RVO, who were treated with intravitreal ranibizumab or aflibercept, and were followed-up for 12 months after initiation of treatment. Five single nucleotide polymorphisms (SNPs) from three different genes (APOE, PON1, SDF-1) were examined as potential predictors for treatment response to intravitreal anti-VEGF agents. RESULTS: Patients with the LL genotype of the PON1 L55M SNP had significantly higher reduction in central subfield thickness (CST) at month 12 after initiation of intravitreal anti-VEGF treatment (101.63 +/- 56.80 mum in LL vs. 72.44 +/- 39.41 mum in LM vs. 40.25 +/- 19.33 mum in MM, p = .026). Patients with the M allele of the PON1 L55M SNP were significantly associated with lower reduction in CST compared to non-carriers (68.29 +/- 38.77 mum in LM + MM vs. 101.63 +/- 56.80 mum in LL, p = .032). CONCLUSION: PON1 L55M SNP may serve as a promising genetic biomarker for predicting response to intravitreal anti-VEGF treatment in patients with macular oedema due to RVO</style></abstract><notes><style face="normal" font="default" size="100%">IS - 1744-5205 (Electronic)IS - 0882-0538 (Linking)LA - engPT - Journal ArticleSB - IM</style></notes></record></records></xml>